January 11, 2019

Deal Snapshot: Eli Lilly And Company & Loxo Oncology

Eli Lilly And Company Logo

Eli Lilly Key BD Contacts

Eli Lilly Deal Activity by Therapeutic Area (Last 3 Years)

33% Oncology, 19% CNS, 20% Diabetes, 14% Immunology, 14% Other

Recent deals:

Eli Lilly Pipeline Composition

33% Oncology, 29% Immunology, 25% Diabetes, 13% CNS

Lead Oncology Assets:

Asset Indication Stage
Ramucirumab Hepatocellular cancer Filed
Pegilodecakin Pancreatic cancer Phase III
Abemaciclib Adjuvant breast cancer Phase III

Business profiles tailored to your asset.